IT201800009282A1 - Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi - Google Patents
Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi Download PDFInfo
- Publication number
- IT201800009282A1 IT201800009282A1 IT102018000009282A IT201800009282A IT201800009282A1 IT 201800009282 A1 IT201800009282 A1 IT 201800009282A1 IT 102018000009282 A IT102018000009282 A IT 102018000009282A IT 201800009282 A IT201800009282 A IT 201800009282A IT 201800009282 A1 IT201800009282 A1 IT 201800009282A1
- Authority
- IT
- Italy
- Prior art keywords
- met
- human
- domain
- amino acid
- antibody fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (28)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009282A IT201800009282A1 (it) | 2018-10-09 | 2018-10-09 | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| SG11202103575RA SG11202103575RA (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| EP22206743.1A EP4194469A1 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| JP2021518891A JP7371093B2 (ja) | 2018-10-09 | 2019-10-07 | 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ |
| IL282033A IL282033B2 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of tumors and/or metastases |
| ES19808675T ES2938714T3 (es) | 2018-10-09 | 2019-10-07 | Fab-Fc anti-Met para el tratamiento de un tumor y/o metástasis |
| SM20230053T SMT202300053T1 (it) | 2018-10-09 | 2019-10-07 | Fab-fc anti-met per il trattamento di un tumore e/o metastasi |
| SI201930456T SI3864050T1 (sl) | 2018-10-09 | 2019-10-07 | Anti-Met Fab-Fc za zdravljenje tumorja in/ali metastaze |
| KR1020217013513A KR102814490B1 (ko) | 2018-10-09 | 2019-10-07 | 종양 및/또는 전이의 치료를 위한 항-Met Fab-Fc |
| PT198086753T PT3864050T (pt) | 2018-10-09 | 2019-10-07 | Fab-fc anti-met para o tratamento de um tumor e/ou metástase |
| DK19808675.3T DK3864050T5 (da) | 2018-10-09 | 2019-10-07 | Anti-met-fab-fc til behandling af en tumor og/eller metastase |
| KR1020257016475A KR20250078600A (ko) | 2018-10-09 | 2019-10-07 | 종양 및/또는 전이의 치료를 위한 항-Met Fab-Fc |
| US17/283,482 US12209129B2 (en) | 2018-10-09 | 2019-10-07 | Anti-Met fab-Fc for the treatment of a tumor and/or metastasis |
| AU2019358417A AU2019358417B2 (en) | 2018-10-09 | 2019-10-07 | Anti-Met Fab-Fc for the treatment of a tumor and/or metastasis |
| CN202411779087.7A CN119587692A (zh) | 2018-10-09 | 2019-10-07 | 用于治疗肿瘤和/或转移的抗Met Fab-Fc |
| PCT/EP2019/077116 WO2020074459A1 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| RS20230107A RS63960B1 (sr) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc za lečenje tumora i/ili metastaza |
| CN201980080611.2A CN113330032B (zh) | 2018-10-09 | 2019-10-07 | 用于治疗肿瘤和/或转移的抗Met Fab-Fc |
| HUE19808675A HUE060843T2 (hu) | 2018-10-09 | 2019-10-07 | Anti-Met Fab-Fc tumor és/vagy metasztázis kezelésére |
| EP19808675.3A EP3864050B1 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| CA3115582A CA3115582A1 (en) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| HRP20230154TT HRP20230154T1 (hr) | 2018-10-09 | 2019-10-07 | Anti-met fab-fc za liječenje tumora i/ili metastaza |
| PL19808675.3T PL3864050T3 (pl) | 2018-10-09 | 2019-10-07 | FAB-FC ANTY-MET do leczenia nowotworu i/lub przerzutu |
| FIEP19808675.3T FI3864050T3 (fi) | 2018-10-09 | 2019-10-07 | Anti-met-fab-fc kasvaimen ja/tai metastaasin hoitamiseksi |
| LTEPPCT/EP2019/077116T LT3864050T (lt) | 2018-10-09 | 2019-10-07 | Fab-fc prieš met, skirtas auglio ir (arba) metastazių gydymui |
| CY20231100073T CY1125831T1 (el) | 2018-10-09 | 2023-02-09 | Αντι-met fab-fc για τη θεραπεια ενος ογκου ή/και μεταστασης |
| US18/973,463 US20250101115A1 (en) | 2018-10-09 | 2024-12-09 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
| AU2026201438A AU2026201438A1 (en) | 2018-10-09 | 2026-02-26 | Anti-met fab-fc for the treatment of a tumor and/or metastasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000009282A IT201800009282A1 (it) | 2018-10-09 | 2018-10-09 | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201800009282A1 true IT201800009282A1 (it) | 2020-04-09 |
Family
ID=65010823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102018000009282A IT201800009282A1 (it) | 2018-10-09 | 2018-10-09 | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12209129B2 (enExample) |
| EP (2) | EP3864050B1 (enExample) |
| JP (1) | JP7371093B2 (enExample) |
| KR (2) | KR20250078600A (enExample) |
| CN (2) | CN119587692A (enExample) |
| AU (2) | AU2019358417B2 (enExample) |
| CA (1) | CA3115582A1 (enExample) |
| CY (1) | CY1125831T1 (enExample) |
| DK (1) | DK3864050T5 (enExample) |
| ES (1) | ES2938714T3 (enExample) |
| FI (1) | FI3864050T3 (enExample) |
| HR (1) | HRP20230154T1 (enExample) |
| HU (1) | HUE060843T2 (enExample) |
| IL (1) | IL282033B2 (enExample) |
| IT (1) | IT201800009282A1 (enExample) |
| LT (1) | LT3864050T (enExample) |
| PL (1) | PL3864050T3 (enExample) |
| PT (1) | PT3864050T (enExample) |
| RS (1) | RS63960B1 (enExample) |
| SG (1) | SG11202103575RA (enExample) |
| SI (1) | SI3864050T1 (enExample) |
| SM (1) | SMT202300053T1 (enExample) |
| WO (1) | WO2020074459A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121443643A (zh) | 2023-06-01 | 2026-01-30 | 皮埃尔法布雷医药公司 | 基于沉默抗体的抗met构建体用于治疗肿瘤和转移 |
| WO2026087699A1 (en) | 2024-10-24 | 2026-04-30 | Pierre Fabre Medicament | New treatment of non-small cell lung cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063816A2 (en) * | 2003-12-19 | 2005-07-14 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| WO2007090807A1 (en) | 2006-02-06 | 2007-08-16 | Metheresis Translational Research S.A. | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| WO2013033008A2 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| WO2014108829A1 (en) * | 2013-01-09 | 2014-07-17 | Metheresis Translational Research S.A. | New antibody fragments, compositions and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650822C (en) * | 2006-04-28 | 2017-03-14 | Esbatech Ag | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk |
| KR101837053B1 (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 |
| JP5734201B2 (ja) * | 2008-12-19 | 2015-06-17 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| PE20120877A1 (es) * | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| EP2500036B1 (en) * | 2011-03-18 | 2014-05-07 | Metheresis Translational Research SA | MET inhibitors for enhancing radiotherapy efficacy |
| ES2785081T3 (es) * | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
| SG11201402485UA (en) | 2011-11-21 | 2014-06-27 | Genentech Inc | Purification of anti-c-met antibodies |
| GB201403875D0 (en) * | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| EP3571221A2 (en) * | 2017-01-20 | 2019-11-27 | Juno Therapeutics GmbH | Cell surface conjugates and related cell compositions and methods |
-
2018
- 2018-10-09 IT IT102018000009282A patent/IT201800009282A1/it unknown
-
2019
- 2019-10-07 KR KR1020257016475A patent/KR20250078600A/ko active Pending
- 2019-10-07 PT PT198086753T patent/PT3864050T/pt unknown
- 2019-10-07 JP JP2021518891A patent/JP7371093B2/ja active Active
- 2019-10-07 DK DK19808675.3T patent/DK3864050T5/da active
- 2019-10-07 ES ES19808675T patent/ES2938714T3/es active Active
- 2019-10-07 RS RS20230107A patent/RS63960B1/sr unknown
- 2019-10-07 EP EP19808675.3A patent/EP3864050B1/en active Active
- 2019-10-07 KR KR1020217013513A patent/KR102814490B1/ko active Active
- 2019-10-07 PL PL19808675.3T patent/PL3864050T3/pl unknown
- 2019-10-07 CA CA3115582A patent/CA3115582A1/en active Pending
- 2019-10-07 FI FIEP19808675.3T patent/FI3864050T3/fi active
- 2019-10-07 HU HUE19808675A patent/HUE060843T2/hu unknown
- 2019-10-07 EP EP22206743.1A patent/EP4194469A1/en active Pending
- 2019-10-07 WO PCT/EP2019/077116 patent/WO2020074459A1/en not_active Ceased
- 2019-10-07 CN CN202411779087.7A patent/CN119587692A/zh active Pending
- 2019-10-07 HR HRP20230154TT patent/HRP20230154T1/hr unknown
- 2019-10-07 SI SI201930456T patent/SI3864050T1/sl unknown
- 2019-10-07 SG SG11202103575RA patent/SG11202103575RA/en unknown
- 2019-10-07 IL IL282033A patent/IL282033B2/en unknown
- 2019-10-07 CN CN201980080611.2A patent/CN113330032B/zh active Active
- 2019-10-07 LT LTEPPCT/EP2019/077116T patent/LT3864050T/lt unknown
- 2019-10-07 US US17/283,482 patent/US12209129B2/en active Active
- 2019-10-07 AU AU2019358417A patent/AU2019358417B2/en active Active
- 2019-10-07 SM SM20230053T patent/SMT202300053T1/it unknown
-
2023
- 2023-02-09 CY CY20231100073T patent/CY1125831T1/el unknown
-
2024
- 2024-12-09 US US18/973,463 patent/US20250101115A1/en active Pending
-
2026
- 2026-02-26 AU AU2026201438A patent/AU2026201438A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063816A2 (en) * | 2003-12-19 | 2005-07-14 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| WO2007090807A1 (en) | 2006-02-06 | 2007-08-16 | Metheresis Translational Research S.A. | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| WO2013033008A2 (en) * | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| WO2014108829A1 (en) * | 2013-01-09 | 2014-07-17 | Metheresis Translational Research S.A. | New antibody fragments, compositions and uses thereof |
Non-Patent Citations (37)
| Title |
|---|
| "Sequences of proteins of immunological interest", vol. 1, 1991, pages: 688 - 696 |
| ATWELL S; RIDGWAY JB; WELLS JA; CARTER P: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library", J MOL BIOL, vol. 270, no. 1, 1997, pages 26 - 35, XP004453749, DOI: doi:10.1006/jmbi.1997.1116 |
| BASILICO C; MODICA C; MAIONE F; VIGNA E; COMOGLIO PM: "Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody- ''decoy'' strategy", INT J CANCER, 25 April 2018 (2018-04-25) |
| BLOOM JW; MADANAT MS; MARRIOTT D; WONG T; CHAN SY: "Intrachain disulfide bond in the core hinge region of human IgG4", PROTEIN SCI, vol. 6, no. 2, 1997, pages 407 - 415, XP002329379 |
| BORK P; DOERKS T; SPRINGER TA; SNEL B: "Domains in plexins: links to integrins and transcription factors", TRENDS BIOCHEM SCI, vol. 24, no. 7, 1999, pages 261 - 263, XP004171834, DOI: doi:10.1016/S0968-0004(99)01416-4 |
| COMOGLIO PM; TRUSOLINO L; BOCCACCIO C.: "Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy", NAT REV CANCER, vol. 18, no. 6, 2018, pages 341 - 358 |
| FERRACINI R; LONGATI P; NALDINI L; VIGNA E; COMOGLIO PM: "Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase", J BIOL CHEM, vol. 266, no. 29, 1991, pages 19558 - 19564, XP000941367 |
| FOVEAU B; ANCOT F; LEROY C; PETRELLI A; REISS K; VINGTDEUX V ET AL.: "Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis", MOL BIOL CELL, vol. 20, no. 9, 2009, pages 2495 - 2507 |
| G. PACCHIANA ET AL: "Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 46, 12 November 2010 (2010-11-12), pages 36149 - 36157, XP055086806, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.134031 * |
| GANDINO L; LONGATI P; MEDICO E; PRAT M; COMOGLIO PM: "Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase", J BIOL CHEM, vol. 269, no. 3, 1994, pages 1815 - 1820, XP002906269 |
| GARCIA-DIAZ A; SHIN DS; MORENO BH; SACO J; ESCUIN-ORDINAS H; RODRIGUEZ GA ET AL.: "Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression", CELL REP, vol. 19, no. 6, 2017, pages 1189 - 1201 |
| GHERARDI E; LOVE CA; ESNOUF RM; JONES EY: "The sema domain", CURR OPIN STRUCT BIOL, vol. 14, no. 6, 2004, pages 669 - 678, XP005764679, DOI: doi:10.1016/j.sbi.2004.10.010 |
| HARRIS WJ: "Production of humanized monoclonal antibodies for in vivo imaging and therapy", BIOCHEM SOC TRANS, vol. 23, no. 4, 1995, pages 1035 - 1038 |
| HUMPHREYS DP; CHAPMAN AP; REEKS DG; LANG V; STEPHENS PE: "Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions", J IMMUNOL METHODS, vol. 209, no. 2, 1997, pages 193 - 202, XP004103797, DOI: doi:10.1016/S0022-1759(97)00172-5 |
| HURLE MR; GROSS M: "Protein engineering techniques for antibody humanization", CURR OPIN BIOTECHNOL, vol. 5, no. 4, 1994, pages 428 - 433, XP023601527, DOI: doi:10.1016/0958-1669(94)90053-1 |
| JANEWAY ET AL.: "Immuno Biology: the immune system in health and disease", 1999, ELSEVIER SCIENCE LTD. |
| JONES PT; DEAR PH; FOOTE J; NEUBERGER MS; WINTER G: "Replacing the complementarity-determining regions in a human antibody with those from a mouse", NATURE, vol. 321, no. 6069, 1986, pages 522 - 525 |
| KONG-BELTRAN M; SESHAGIRI S; ZHA J; ZHU W; BHAWE K; MENDOZA N ET AL.: "Somatic mutations lead to an oncogenic deletion of met in lung cancer", CANCER RES, vol. 66, no. 1, 2006, pages 283 - 289, XP002474266, DOI: doi:10.1158/0008-5472.CAN-05-2749 |
| MAKABE K; NAKANISHI T; TSUMOTO K; TANAKA Y; KONDO H; UMETSU M ET AL.: "Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528", J BIOL CHEM, vol. 283, no. 2, 17 October 2007 (2007-10-17), pages 1156 - 1166, XP055110460, DOI: doi:10.1074/jbc.M706190200 |
| MANIATIS T.: "Molecular cloning: A laboratory manual", 1982, COLD SPRING HARBOR LABORATORY |
| PACCHIANA G; CHIRIACO C; STELLA MC; PETRONZELLI F; DE SANTIS R; GALLUZZO M ET AL.: "Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody", J BIOL CHEM, vol. 285, no. 46, 10 September 2010 (2010-09-10), pages 36149 - 36157 |
| PETRELLI A; GILESTRO GF; LANZARDO S; COMOGLIO PM; MIGONE N; GIORDANO S: "The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met", NATURE, vol. 416, no. 6877, 2002, pages 187 - 190 |
| PONZETTO C; BARDELLI A; ZHEN Z; MAINA F; DALLA ZONCA P; GIORDANO S ET AL.: "A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family", CELL, vol. 77, no. 2, 1994, pages 261 - 271, XP024245267, DOI: doi:10.1016/0092-8674(94)90318-2 |
| PRAT M; CREPALDI T; PENNACCHIETTI S; BUSSOLINO F; COMOGLIO PM: "Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF", J CELL SCI, vol. 111, 1998, pages 237 - 247, XP055561472 |
| PRESTA LG: "Antibody engineering", CURR OPIN BIOTECHNOL, vol. 3, no. 4, 1992, pages 394 - 398, XP023601588, DOI: doi:10.1016/0958-1669(92)90168-I |
| REGE-CAMBRIN G; SCARAVAGLIO P; CAROZZI F; GIORDANO S; PONZETTO C; COMOGLIO PM ET AL.: "Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene", CANCER GENET CYTOGENET, vol. 64, no. 2, 1992, pages 170 - 173, XP025212176, DOI: doi:10.1016/0165-4608(92)90350-H |
| REMINGTON, PHARMACEUTICAL SCIENCES, 1980 |
| REMINGTON: "Pharmaceutical Sciences", 1980 |
| RIDGWAY JB; PRESTA LG; CARTER P: "Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", PROTEIN ENG, vol. 9, no. 7, 1996, pages 617 - 621, XP002610995, DOI: doi:10.1093/protein/9.7.617 |
| RIECHMANN L; CLARK M; WALDMANN H; WINTER G: "Reshaping human antibodies for therapy", NATURE, vol. 332, no. 6162, 1988, pages 323 - 327, XP000020414, DOI: doi:10.1038/332323a0 |
| SCHELTER F; KOBUCH J; MOSS ML; BECHERER JD; COMOGLIO PM ET AL.: "Boccaccio C et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor", J BIOL CHEM, vol. 285, no. 34, 2010, pages 26335 - 26340, XP055389374, DOI: doi:10.1074/jbc.M110.106435 |
| TRUSOLINO L; BERTOTTI A; COMOGLIO PM: "MET signalling: principles and functions in development, organ regeneration and cancer", NAT REV MOL CELL BIOL, vol. 11, no. 12, 2010, pages 834 - 848, XP055087504, DOI: doi:10.1038/nrm3012 |
| VASWANI SK; HAMILTON RG: "Humanized antibodies as potential therapeutic drugs", ANN ALLERGY ASTHMA IMMUNOL, vol. 81, no. 2, 1998, pages 105 - 115, XP026957802 |
| VIGNA E; CHIRIACO C; CIGNETTO S; FONTANI L; BASILICO C; PETRONZELLI F ET AL.: "Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30", MOL ONCOL, vol. 9, no. 9, 2015, pages 1760 - 1772, XP055425203, DOI: doi:10.1016/j.molonc.2015.05.007 |
| WATTS H F ET AL: "Activation of complement pathways by univalent antibody derivatives with intact Fc zones", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 22, no. 7, 1 July 1985 (1985-07-01), pages 803 - 810, XP023852735, ISSN: 0161-5890, [retrieved on 19850701], DOI: 10.1016/0161-5890(85)90146-4 * |
| ZHU Z; PRESTA LG; ZAPATA G; CARTER P: "Remodeling domain interfaces to enhance heterodimer formation", PROTEIN SCI, vol. 6, no. 4, 1997, pages 781 - 788, XP055345091, DOI: doi:10.1002/pro.5560060404 |
| ZOU W; CHEN L: "Inhibitory B7-family molecules in the tumour microenvironment", NAT REV IMMUNOL, vol. 8, no. 6, 2008, pages 467 - 477, XP009142446, DOI: doi:10.1038/nri2326 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162941B2 (en) | Anti-CD112R compositions and methods | |
| CN111601826B (zh) | 针对tigit的抗体及其变体 | |
| JP7267280B2 (ja) | Ｔｒｅｍ１を発現する骨髄細胞を無能化させるための組成物および方法 | |
| JP2023055871A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| ES2835823T3 (es) | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 | |
| TWI731861B (zh) | FcRH5之人源化及親和力成熟抗體及使用方法 | |
| ES2816624T3 (es) | Anticuerpos que se unen a EGFR y ERBB3 | |
| KR102845020B1 (ko) | Pd-l1에 대한 항체 및 변이체 | |
| US20250101115A1 (en) | Anti-met fab-fc for the treatment of a tumor and/or metastasis | |
| JP2023508218A (ja) | 抗ｏｘ４０抗体およびその使用 | |
| TW200948380A (en) | Combination of HGF inhibitor and PTEN agonist to treat cancer | |
| IT201800003875A1 (it) | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi | |
| HK40119612A (en) | Anti-met fab-fc for the treatment of a tumor and/or metastasis |